Albumin-bilirubin (ALBI) and Platelet-ALBI (PALBI) Grades: Novel Prognostic Factors for Cholangiocellular Carcinoma.

IF 1.8 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL
In vivo Pub Date : 2025-09-01 DOI:10.21873/invivo.14098
Ergin Aydemir, Funda Yilmaz, Alper Türkel, Öztürk Ateş, Mutlu Doğan
{"title":"Albumin-bilirubin (ALBI) and Platelet-ALBI (PALBI) Grades: Novel Prognostic Factors for Cholangiocellular Carcinoma.","authors":"Ergin Aydemir, Funda Yilmaz, Alper Türkel, Öztürk Ateş, Mutlu Doğan","doi":"10.21873/invivo.14098","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aim: </strong>Cholangiocarcinoma (CCA) is the second most frequently occurring primary malignant tumor of the liver, characterized by poor survival due to late diagnosis and limited treatment options. The albumin-bilirubin (ALBI) and platelet-ALBI (PALBI) scores, which reflect liver function and inflammation, have emerged as potential prognostic markers in hepatocellular carcinoma (HCC). Their prognostic significance in CCA, however, remains less established.</p><p><strong>Patients and methods: </strong>A retrospective analysis was conducted on 184 patients diagnosed with CCA between 2007 and 2024. The study evaluated the relationship between tumor location, ALBI/PALBI grades, and overall survival (OS). Patients were categorized into three groups based on their ALBI and PALBI scores, and survival outcomes were analyzed.</p><p><strong>Results: </strong>Tumor location significantly impacted OS. The median OS (mOS) was 18 months for distal CCA, 13 months for perihilar CCA, and 7 months for intrahepatic CCA (<i>p</i><0.001). When stratified by ALBI grade, mOS was 17 months for Grade 1, 8 months for Grade 2, and 2 months for Grade 3 (<i>p</i>=0.001). Similarly, for PALBI grade, mOS was 13 months for Grade A1, 11 months for Grade A2, and 8 months for Grade A3 (<i>p</i>=0.037). Among the variables included in the multivariate analysis, only the ALBI grade retained its significance as an independent prognostic factor for overall survival.</p><p><strong>Conclusion: </strong>ALBI and PALBI grades serve as effective prognostic indicators in CCA, with lower grades associated with enhanced survival rates. Notably, ALBI grade was found to be an independent predictor of OS, presenting a cost-efficient biomarker that may support clinical decision-making by providing crucial prognostic information insights.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 5","pages":"2976-2985"},"PeriodicalIF":1.8000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12396068/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"In vivo","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/invivo.14098","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background/aim: Cholangiocarcinoma (CCA) is the second most frequently occurring primary malignant tumor of the liver, characterized by poor survival due to late diagnosis and limited treatment options. The albumin-bilirubin (ALBI) and platelet-ALBI (PALBI) scores, which reflect liver function and inflammation, have emerged as potential prognostic markers in hepatocellular carcinoma (HCC). Their prognostic significance in CCA, however, remains less established.

Patients and methods: A retrospective analysis was conducted on 184 patients diagnosed with CCA between 2007 and 2024. The study evaluated the relationship between tumor location, ALBI/PALBI grades, and overall survival (OS). Patients were categorized into three groups based on their ALBI and PALBI scores, and survival outcomes were analyzed.

Results: Tumor location significantly impacted OS. The median OS (mOS) was 18 months for distal CCA, 13 months for perihilar CCA, and 7 months for intrahepatic CCA (p<0.001). When stratified by ALBI grade, mOS was 17 months for Grade 1, 8 months for Grade 2, and 2 months for Grade 3 (p=0.001). Similarly, for PALBI grade, mOS was 13 months for Grade A1, 11 months for Grade A2, and 8 months for Grade A3 (p=0.037). Among the variables included in the multivariate analysis, only the ALBI grade retained its significance as an independent prognostic factor for overall survival.

Conclusion: ALBI and PALBI grades serve as effective prognostic indicators in CCA, with lower grades associated with enhanced survival rates. Notably, ALBI grade was found to be an independent predictor of OS, presenting a cost-efficient biomarker that may support clinical decision-making by providing crucial prognostic information insights.

Abstract Image

Abstract Image

Abstract Image

白蛋白-胆红素(ALBI)和血小板-胆红素(PALBI)分级:胆管细胞癌的新预后因素
背景/目的:胆管癌(CCA)是第二常见的肝脏原发性恶性肿瘤,由于诊断较晚和治疗方案有限,其特点是生存率低。反映肝功能和炎症的白蛋白-胆红素(ALBI)和血小板-胆红素(PALBI)评分已成为肝细胞癌(HCC)的潜在预后指标。然而,它们在CCA中的预后意义仍不太确定。患者和方法:回顾性分析2007年至2024年诊断为CCA的184例患者。该研究评估了肿瘤位置、ALBI/PALBI分级和总生存期(OS)之间的关系。根据ALBI和PALBI评分将患者分为三组,并对生存结果进行分析。结果:肿瘤位置对OS有显著影响。中位OS (mOS)远端CCA为18个月,门周CCA为13个月,肝内CCA为7个月(pp=0.001)。同样,对于PALBI分级,A1级的最小生存期为13个月,A2级为11个月,A3级为8个月(p=0.037)。在多变量分析中包含的变量中,只有ALBI分级保留了其作为总生存的独立预后因素的重要性。结论:ALBI和PALBI分级是CCA的有效预后指标,分级越低生存率越高。值得注意的是,ALBI分级被发现是OS的独立预测因子,它是一种具有成本效益的生物标志物,可以通过提供关键的预后信息来支持临床决策。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
In vivo
In vivo 医学-医学:研究与实验
CiteScore
4.20
自引率
4.30%
发文量
330
审稿时长
3-8 weeks
期刊介绍: IN VIVO is an international peer-reviewed journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of physiology, pathology and disease management. The topics of IN VIVO include: 1. Experimental development and application of new diagnostic and therapeutic procedures; 2. Pharmacological and toxicological evaluation of new drugs, drug combinations and drug delivery systems; 3. Clinical trials; 4. Development and characterization of models of biomedical research; 5. Cancer diagnosis and treatment; 6. Immunotherapy and vaccines; 7. Radiotherapy, Imaging; 8. Tissue engineering, Regenerative medicine; 9. Carcinogenesis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信